Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...

The amount of credits the company receives is contingent upon its meeting job creation and capital investment goals.

The Wisconsin Economic Development Corp. is offering pharmaceutical giant Eli Lilly up to $100 million in tax credits to ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

Eli Lilly is eligible for 100M in tax credits to expand its Pleasant Prairie facility, adding 750 jobs and boosting Wisconsin ...

It’s not clear just how many new jobs the investment will bring, though it is likely that a lot of the investment will be in automation.

Pharmaceutical giant Eli Lilly and Company is receiving up to $100 million in performance-based state tax credits, Wisconsin ...

Many younger professionals are finding luck launching careers in second-tier cities like Raleigh, Milwaukee and Birmingham, a new analysis shows.

Eli Lilly and Company, a pharmaceutical manufacturing facility, will be receiving up to $100 million in performance-based state tax credits for its $4 billion investment in Wisconsin.

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral GLP-1 candidate will soon report key phase 3 results in weight ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.